<p>MDxHealth SA (NASDAQ:MDXH - 獲取免費報告) 在 12 月份的空頭頭寸大幅減少。截至 12 月 15 日，空頭頭寸總計 15,027 股，比 11 月 30 日的 26,198 股減少了 42.6%。根據 122,196 股的平均日交易量，當前的覆蓋天數比率為 0.1 天。目前，公司股票的空頭比例為 0.0%。</p>
<h2>MDxHealth 股價下跌 1.7%</h2>
<p>NASDAQ:MDXH 週五下跌 0.06 美元，報 3.41 美元。該公司的股票交易量為 42,254 股，而其平均交易量為 110,342 股。該股票的 50 日移動平均價格為 3.84 美元，200 日移動平均價格為 3.37 美元。MDxHealth 的 12 個月低點為 1.35 美元，12 個月高點為 5.33 美元。該公司的速動比率為 1.02，流動比率為 1.14，債務股本比率為 13.81。該公司的市值為 1.6126 億美元，市盈率為-5.33，貝塔值為 1.59。</p>
<p>MDxHealth (NASDAQ:MDXH - 獲取免費報告) 最近於 11 月 12 日發佈了季度財報。該公司報告每股收益（EPS）為-0.16 美元，低於分析師一致預期的-0.12 美元，差距為 0.04 美元。MDxHealth 的淨利潤率為-30.50%，股本回報率為-1,078.01%。該公司在本季度的收入為 2743 萬美元，而分析師預期為 2411 萬美元。平均而言，股票分析師預計 MDxHealth 在當前財政年度的每股收益為-1.15 美元。</p>
<h2>MDxHealth 的機構交易</h2>
<p>大型投資者最近調整了對該股票的持有。GSA Capital Partners LLP 在第三季度購買了 MDxHealth 的新股份，價值約 48,000 美元。Lido Advisors LLC 在第三季度獲得了 MDxHealth 的新頭寸，價值約 48,000 美元。Citadel Advisors LLC 在第三季度將其在 MDxHealth 的持股增加了 30.6%。Citadel Advisors LLC 目前擁有 48,938 股該公司的股票，價值 228,000 美元，此前在上個季度購買了 11,456 股。Jefferies Financial Group Inc.在第三季度獲得了 MDxHealth 的新股份，價值約 53,000 美元。最後，Bank of America Corp DE 在第三季度將其在 MDxHealth 的持股增加了 5,164.0%。Bank of America Corp DE 目前擁有 15,055 股該公司的股票，價值 70,000 美元，此前在該期間內購買了 14,769 股。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些股票分析師最近對 MDXH 股票發佈了報告。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 MDxHealth 股票的 “賣出（e+）” 評級。Wall Street Zen 在 8 月 30 日的報告中將 MDxHealth 股票的評級上調至 “持有”。Lake Street Capital 在 11 月 13 日的研究報告中將 MDxHealth 的目標價格從 7.00 美元上調至 9.00 美元，並給予該股票 “買入” 評級。BTIG Research 在 12 月 23 日的報告中重申了 “買入” 評級，並對 MDxHealth 股票設定了 7.00 美元的目標價。最後，TD Cowen 在 11 月 13 日的報告中將 MDxHealth 的目標價格從 5.00 美元上調至 7.00 美元，並給予該股票 “買入” 評級。四位分析師對該股票給予了買入評級，一位分析師對該公司的股票給予了賣出評級。根據 MarketBeat.com 的數據，MDxHealth 目前的共識評級為 “適度買入”，共識目標價格為 7.75 美元。</p>
<p><strong>查看我們關於 MDxHealth 的最新報告</strong></p>
<h2>關於 MDxHealth</h2>
<p>(獲取免費報告)</p>
<p>MDxHealth 總部位於比利時梅赫倫，在美國馬薩諸塞州牛頓設有辦事處，是一家分子診斷公司，專注於通過表觀遺傳生物標誌物檢測提高癌症診斷和治療決策的準確性。該公司專注於開發和商業化檢測與泌尿系統癌症相關的 DNA 甲基化變化的測試，從而實現更精確的風險分層和患者管理。</p>
<p>MDxHealth 的主要產品組合包括 ConfirmMDx 和 SelectMDx。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們更看好的五隻股票比 MDxHealth 更好</li>
<li>華爾街股票挑選者評選 2026 年第一隻股票</li>
<li>“6.6 萬億美元的客户銀行存款面臨風險”</li>
<li>華盛頓為戰爭做準備</li>
<li>崩盤前一個月</li>
<li>現在就拋掉這五隻股票！</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 MDxHealth 嗎？</h2>
<p>在考慮 MDxHealth 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前...而 MDxHealth 並不在名單上。</p>
<p>雖然 MDxHealth 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MDXH

<p>MDxHealth SA (NASDAQ:MDXH) 在 12 月份的空頭頭寸大幅下降，至 12 月 15 日減少了 42.6%，降至 15,027 股。當前的空頭頭寸比率為 0.1 天。該股票在週五下跌了 1.7%，報 3.41 美元。分析師對該股票給予了 “適度買入” 的共識評級，目標價格為 7.75 美元。MDxHealth 專注於癌症的分子診斷，主要產品包括 ConfirmMDx 和 SelectMDx</p>

<p>MDxHealth SA (NASDAQ:MDXH - Get Free Report) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totaling 15,027 shares, a decrease of 42.6% from the November 30th total of 26,198 shares. Based on an average daily trading volume, of 122,196 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company's stock are sold short. Currently, 0.0% of the company's stock are sold short. Based on an average daily trading volume, of 122,196 shares, the days-to-cover ratio is presently 0.1 days.</p>
<div class="lb-trans"><p>MDxHealth SA (NASDAQ:MDXH - 獲取免費報告) 在 12 月份的空頭頭寸大幅減少。截至 12 月 15 日，空頭頭寸總計 15,027 股，比 11 月 30 日的 26,198 股減少了 42.6%。根據 122,196 股的平均日交易量，當前的覆蓋天數比率為 0.1 天。目前，公司股票的空頭比例為 0.0%。</p>
</div><h2>MDxHealth Trading Down 1.7%</h2>
<div class="lb-trans"><h2>MDxHealth 股價下跌 1.7%</h2>
</div><p>NASDAQ:MDXH traded down $0.06 on Friday, reaching $3.41. The company's stock had a trading volume of 42,254 shares, compared to its average volume of 110,342. The stock has a 50 day moving average price of $3.84 and a 200 day moving average price of $3.37. MDxHealth has a 12-month low of $1.35 and a 12-month high of $5.33. The company has a quick ratio of 1.02, a current ratio of 1.14 and a debt-to-equity ratio of 13.81. The firm has a market cap of $161.26 million, a price-to-earnings ratio of -5.33 and a beta of 1.59.</p>
<div class="lb-trans"><p>NASDAQ:MDXH 週五下跌 0.06 美元，報 3.41 美元。該公司的股票交易量為 42,254 股，而其平均交易量為 110,342 股。該股票的 50 日移動平均價格為 3.84 美元，200 日移動平均價格為 3.37 美元。MDxHealth 的 12 個月低點為 1.35 美元，12 個月高點為 5.33 美元。該公司的速動比率為 1.02，流動比率為 1.14，債務股本比率為 13.81。該公司的市值為 1.6126 億美元，市盈率為-5.33，貝塔值為 1.59。</p>
</div><p>MDxHealth (NASDAQ:MDXH - Get Free Report) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.04). MDxHealth had a negative net margin of 30.50% and a negative return on equity of 1,078.01%. The company had revenue of $27.43 million during the quarter, compared to analysts' expectations of $24.11 million. On average, equities analysts anticipate that MDxHealth will post -1.15 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>MDxHealth (NASDAQ:MDXH - 獲取免費報告) 最近於 11 月 12 日發佈了季度財報。該公司報告每股收益（EPS）為-0.16 美元，低於分析師一致預期的-0.12 美元，差距為 0.04 美元。MDxHealth 的淨利潤率為-30.50%，股本回報率為-1,078.01%。該公司在本季度的收入為 2743 萬美元，而分析師預期為 2411 萬美元。平均而言，股票分析師預計 MDxHealth 在當前財政年度的每股收益為-1.15 美元。</p>
</div><h2>Institutional Trading of MDxHealth</h2>
<div class="lb-trans"><h2>MDxHealth 的機構交易</h2>
</div><p>Large investors have recently modified their holdings of the stock. GSA Capital Partners LLP purchased a new stake in MDxHealth during the 3rd quarter worth about $48,000. Lido Advisors LLC acquired a new position in MDxHealth during the third quarter worth approximately $48,000. Citadel Advisors LLC raised its position in MDxHealth by 30.6% in the 3rd quarter. Citadel Advisors LLC now owns 48,938 shares of the company's stock valued at $228,000 after purchasing an additional 11,456 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of MDxHealth during the third quarter worth about $53,000. Finally, Bank of America Corp DE increased its position in MDxHealth by 5,164.0% in the 3rd quarter. Bank of America Corp DE now owns 15,055 shares of the company's stock valued at $70,000 after acquiring an additional 14,769 shares during the period.</p>
<div class="lb-trans"><p>大型投資者最近調整了對該股票的持有。GSA Capital Partners LLP 在第三季度購買了 MDxHealth 的新股份，價值約 48,000 美元。Lido Advisors LLC 在第三季度獲得了 MDxHealth 的新頭寸，價值約 48,000 美元。Citadel Advisors LLC 在第三季度將其在 MDxHealth 的持股增加了 30.6%。Citadel Advisors LLC 目前擁有 48,938 股該公司的股票，價值 228,000 美元，此前在上個季度購買了 11,456 股。Jefferies Financial Group Inc.在第三季度獲得了 MDxHealth 的新股份，價值約 53,000 美元。最後，Bank of America Corp DE 在第三季度將其在 MDxHealth 的持股增加了 5,164.0%。Bank of America Corp DE 目前擁有 15,055 股該公司的股票，價值 70,000 美元，此前在該期間內購買了 14,769 股。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of equities analysts have recently issued reports on MDXH shares. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of MDxHealth in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of MDxHealth to a &#34;hold&#34; rating in a report on Saturday, August 30th. Lake Street Capital raised their target price on MDxHealth from $7.00 to $9.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, November 13th. BTIG Research reaffirmed a &#34;buy&#34; rating and issued a $7.00 price objective on shares of MDxHealth in a report on Tuesday, December 23rd. Finally, TD Cowen raised their target price on MDxHealth from $5.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, MDxHealth presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $7.75.</p>
<div class="lb-trans"><p>一些股票分析師最近對 MDXH 股票發佈了報告。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 MDxHealth 股票的 “賣出（e+）” 評級。Wall Street Zen 在 8 月 30 日的報告中將 MDxHealth 股票的評級上調至 “持有”。Lake Street Capital 在 11 月 13 日的研究報告中將 MDxHealth 的目標價格從 7.00 美元上調至 9.00 美元，並給予該股票 “買入” 評級。BTIG Research 在 12 月 23 日的報告中重申了 “買入” 評級，並對 MDxHealth 股票設定了 7.00 美元的目標價。最後，TD Cowen 在 11 月 13 日的報告中將 MDxHealth 的目標價格從 5.00 美元上調至 7.00 美元，並給予該股票 “買入” 評級。四位分析師對該股票給予了買入評級，一位分析師對該公司的股票給予了賣出評級。根據 MarketBeat.com 的數據，MDxHealth 目前的共識評級為 “適度買入”，共識目標價格為 7.75 美元。</p>
</div><p><strong>View Our Latest Report on MDxHealth</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 MDxHealth 的最新報告</strong></p>
</div><h2>About MDxHealth</h2>
<div class="lb-trans"><h2>關於 MDxHealth</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.</p>
<div class="lb-trans"><p>MDxHealth 總部位於比利時梅赫倫，在美國馬薩諸塞州牛頓設有辦事處，是一家分子診斷公司，專注於通過表觀遺傳生物標誌物檢測提高癌症診斷和治療決策的準確性。該公司專注於開發和商業化檢測與泌尿系統癌症相關的 DNA 甲基化變化的測試，從而實現更精確的風險分層和患者管理。</p>
</div><p>MDxHealth's lead product portfolio includes ConfirmMDx and SelectMDx.</p>
<div class="lb-trans"><p>MDxHealth 的主要產品組合包括 ConfirmMDx 和 SelectMDx。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than MDxHealth</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>“$6.6 Trillion Of Customer Bank Deposits At Risk”</li>
<li>Washington prepares for war</li>
<li>A month before the crash</li>
<li>Drop these 5 stocks now!</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 MDxHealth 更好</li>
<li>華爾街股票挑選者評選 2026 年第一隻股票</li>
<li>“6.6 萬億美元的客户銀行存款面臨風險”</li>
<li>華盛頓為戰爭做準備</li>
<li>崩盤前一個月</li>
<li>現在就拋掉這五隻股票！</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MDxHealth Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 MDxHealth 嗎？</h2>
</div><p>Before you consider MDxHealth, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 MDxHealth 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MDxHealth wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前...而 MDxHealth 並不在名單上。</p>
</div><p>While MDxHealth currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MDxHealth 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

MDxHealth SA（NASDAQ 代碼：MDXH）空頭頭寸更新